Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Roflumilast: a green signal is yet to come.

Literature DB >> 23825748

Roflumilast: a green signal is yet to come.

Nazir Lone¹, Yuji Oba.

Abstract

Year: 2013 PMID： 23825748 PMCID： PMC3698285 DOI： 10.3978/j.issn.2072-1439.2013.05.11

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

18 in total

Review 1. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Authors: Nathan A Pinner; Leslie A Hamilton; Anthony Hughes
Journal: Clin Ther Date: 2012-01 Impact factor: 3.393

2. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care.

Authors: Johanna R Feary; Laura C Rodrigues; Christopher J Smith; Richard B Hubbard; Jack E Gibson
Journal: Thorax Date: 2010-09-25 Impact factor: 9.139

3. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Authors: Milo Puhan
Journal: Cochrane Database Syst Rev Date: 2011-05-11

Review 4. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors: Klaus F Rabe
Journal: Br J Pharmacol Date: 2011-05 Impact factor: 8.739

Review 5. Adverse effects of corticosteroids on the cardiovascular system.

Authors: D E Sholter; P W Armstrong
Journal: Can J Cardiol Date: 2000-04 Impact factor: 5.223

Review 6. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.

Authors: Mark A Giembycz
Journal: Br J Clin Pharmacol Date: 2006-08 Impact factor: 4.335

7. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors: Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal: Eur J Heart Fail Date: 2009-01-27 Impact factor: 15.534

8. Roflumilast: doubtful efficacy but clear harms in COPD.

Authors:
Journal: Prescrire Int Date: 2013-01

9. Hospitalizations and mortality in the Lung Health Study.

Authors: Nicholas R Anthonisen; John E Connett; Paul L Enright; Jure Manfreda
Journal: Am J Respir Crit Care Med Date: 2002-08-01 Impact factor: 21.405

Review 10. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors: Yuji Oba; Nazir A Lone
Journal: Ther Adv Respir Dis Date: 2012-11-29 Impact factor: 4.031

1 in total

1. Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD.

Authors: Milo A Puhan; Tsung Yu; Cynthia M Boyd; Gerben Ter Riet
Journal: BMC Med Date: 2015-07-02 Impact factor: 8.775

1 in total